157 related articles for article (PubMed ID: 21764128)
1. Primary cutaneous CD30 positive anaplastic large cell lymphoma--report of a case treated with bexarotene.
Oliveira A; Fernandes I; Alves R; Lima M; Selores M
Leuk Res; 2011 Nov; 35(11):e190-2. PubMed ID: 21764128
[No Abstract] [Full Text] [Related]
2. Localized perineal cutaneous nodules: a case of recurrent systemic anaplastic large-cell lymphoma.
Hernandez C; Puangsuvan SN; Peterson A; Robinson JK
Clin Exp Dermatol; 2009 Dec; 34(8):e722-5. PubMed ID: 20055841
[TBL] [Abstract][Full Text] [Related]
3. Long-term bexarotene monotherapy in large cell CD30+ pleomorphic T-cell lymphoma.
Aldaoud A
Dermatol Clin; 2008 Jan; 26 Suppl 1():15-7. PubMed ID: 18405181
[No Abstract] [Full Text] [Related]
4. Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma.
Shehan JM; Kalaaji AN; Markovic SN; Ahmed I
J Am Acad Dermatol; 2004 Jul; 51(1):103-10. PubMed ID: 15243534
[TBL] [Abstract][Full Text] [Related]
5. Folliculotropic mycosis fungoides with CD30+ large-cell transformation in a young woman: beneficial effect of bexarotene.
Mitteldorf C; Stadler R; Bertsch HP; Neumann C
Br J Dermatol; 2007 Mar; 156(3):584-6. PubMed ID: 17300259
[No Abstract] [Full Text] [Related]
6. Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
Isogai R; Fukao M; Kawada A
J Dermatol; 2007 Aug; 34(8):556-60. PubMed ID: 17683387
[TBL] [Abstract][Full Text] [Related]
7. Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature.
Kumar S; Pittaluga S; Raffeld M; Guerrera M; Seibel NL; Jaffe ES
Pediatr Dev Pathol; 2005; 8(1):52-60. PubMed ID: 15719203
[TBL] [Abstract][Full Text] [Related]
8. [T-cell primary chest wall anaplastic large cell lymphoma--a case report].
Yu ZY; Yang G; Ouyang XN; Yao LQ
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1656. PubMed ID: 16185543
[No Abstract] [Full Text] [Related]
9. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy.
French LE; Shapiro M; Junkins-Hopkins JM; Vittorio CC; Rook AH
J Am Acad Dermatol; 2001 Dec; 45(6):914-8. PubMed ID: 11712039
[TBL] [Abstract][Full Text] [Related]
10. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
11. Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis.
Sheehy O; Catherwood M; Pettengell R; Morris TC
Leuk Lymphoma; 2009 Aug; 50(8):1389-91. PubMed ID: 19544141
[No Abstract] [Full Text] [Related]
12. Primary cutaneous CD30 positive anaplastic large cell lymphoma in an adolescent.
Vaid R; Cohen B
Pediatr Dermatol; 2009; 26(6):721-4. PubMed ID: 20199449
[TBL] [Abstract][Full Text] [Related]
13. Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.
Patsinakidis N; Kreuter A; Moritz RK; Stücker M; Altmeyer P; Möllenhoff K
Acta Derm Venereol; 2015 Feb; 95(2):233-4. PubMed ID: 24733422
[No Abstract] [Full Text] [Related]
14. Cutaneous intravascular anaplastic large cell lymphoma.
Wang L; Li C; Gao T
J Cutan Pathol; 2011 Feb; 38(2):221-6. PubMed ID: 20337769
[TBL] [Abstract][Full Text] [Related]
15. Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene.
Mehlmauer MA
Cutis; 2004 Jun; 73(6):417-20. PubMed ID: 15224787
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
17. Selective IgM deficiency in CD30+ cutaneous lymphoproliferative disorder.
Saini S; Dettore AJ; Bhambhani KJ; Buck S; Poulik J; Savaşan S
J Pediatr Hematol Oncol; 2011 May; 33(4):e156-9. PubMed ID: 21516014
[TBL] [Abstract][Full Text] [Related]
18. Topical and oral bexarotene.
Schadt CR
Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
[TBL] [Abstract][Full Text] [Related]
19. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
20. Primary cutaneous anaplastic CD30 + large-cell lymphoma that completely regressed after incisional skin biopsy.
Gencoglan G; Ozturk F; Inanir I; Miskioglu M; Temiz P; Gunduz K
Cutan Ocul Toxicol; 2011 Jun; 30(2):163-6. PubMed ID: 21083511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
